Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Combination therapy for high-risk MDS? Not quite yet

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Combination therapy for high-risk MDS? Not quite yet ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

ASH 2014: Highlights in mantle cell lymphoma

Prof Steven Le Gouill and Prof Simon Rule

ASH 2014: Highlights in mantle cell lymphoma ( Prof Steven Le Gouill and Prof Simon Rule )

ASH 2014: Highlights in multiple myeloma

Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios...

ASH 2014: Highlights in multiple myeloma ( Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimopoulos )

Tyrosine kinase inhibitor in combination with chemo shows benefit in acute...

Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany

Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )

Paediatric leukaemia treatment regimens lead to improved outcomes in...

Dr Wendy Stock - University of Chicago, Chicago, USA

Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults ( Dr Wendy Stock - University of Chicago, Chicago, USA )

Targeted therapy effective in elderly patients with Philadelphia-positive acute...

Dr Oliver Ottmann - Goethe University, Frankfurt, Germany

Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia ( Dr Oliver Ottmann - Goethe University, Frankfurt, Germany )

First randomised evidence for benefit from adding a tyrosine kinase inhibitor...

Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany

First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )

Chemo-free treatment approach demonstrates positive responses in leukaemia...

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

Chemo-free treatment approach demonstrates positive responses in leukaemia patients ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Nivolumab shows early promise in Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA

Nivolumab shows early promise in Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )

Blinatumomab demonstrates significant clinical activity in residual ALL

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

Blinatumomab demonstrates significant clinical activity in residual ALL ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

New immunotherapy compound effective, safe in ALL patients with minimal...

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany

New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )

More from ecancer